Mar. 17 at 1:36 PM
$AUPH https://clinicaltrials.gov/study/NCT07473986 this was just updated yesterday.
In Italy, following the publication of AIFA determination N. 42 of 19.02.2022, starting from 20.02.2022 it is possible to use the combination of Evusheld monoclonal antibodies (Tixagevimab-Cilgavimab) in specific and defined categories of patients who have severe immune system impairment including solid organ transplant recipients.
I wonder if the data shows it is possible to use it with patients on voclosporin? AZN is already developing the next gen Evusheld in AZD3152.
The timing is interesting as we devle into the colitis angle, considering one long covid symptom is leaky gut. AZN very interested in long covid and colitis as our IP for covid treatment comes close....
